Clinical Trial Results: Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating magrolimab plus pembrolizumab in relapsed or refractory classic Hodgkin lymphoma has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classic Hodgkin Lymphoma
• Classical Hodgkin Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Magrolimab (magrolimab)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Ranjana Advani | Conditions: Hodgkin Lymphoma, Classic Hodgkin Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2026-06-30